Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany

Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-...

Descripción completa

Detalles Bibliográficos
Autores principales: Koehler, Johanna, Ritzer, Barbara, Weidlich, Simon, Gebhardt, Friedemann, Kirchhoff, Chlodwig, Gempt, Jens, Querbach, Christiane, Hoffmann, Dieter, Haller, Bernhard, Schmid, Roland M., Schneider, Jochen, Spinner, Christoph D., Iakoubov, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269399/
https://www.ncbi.nlm.nih.gov/pubmed/34244967
http://dx.doi.org/10.1007/s15010-021-01657-y
_version_ 1783720570994556928
author Koehler, Johanna
Ritzer, Barbara
Weidlich, Simon
Gebhardt, Friedemann
Kirchhoff, Chlodwig
Gempt, Jens
Querbach, Christiane
Hoffmann, Dieter
Haller, Bernhard
Schmid, Roland M.
Schneider, Jochen
Spinner, Christoph D.
Iakoubov, Roman
author_facet Koehler, Johanna
Ritzer, Barbara
Weidlich, Simon
Gebhardt, Friedemann
Kirchhoff, Chlodwig
Gempt, Jens
Querbach, Christiane
Hoffmann, Dieter
Haller, Bernhard
Schmid, Roland M.
Schneider, Jochen
Spinner, Christoph D.
Iakoubov, Roman
author_sort Koehler, Johanna
collection PubMed
description Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s15010-021-01657-y.
format Online
Article
Text
id pubmed-8269399
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-82693992021-07-09 Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany Koehler, Johanna Ritzer, Barbara Weidlich, Simon Gebhardt, Friedemann Kirchhoff, Chlodwig Gempt, Jens Querbach, Christiane Hoffmann, Dieter Haller, Bernhard Schmid, Roland M. Schneider, Jochen Spinner, Christoph D. Iakoubov, Roman Infection Brief Report Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s15010-021-01657-y. Springer Berlin Heidelberg 2021-07-09 2021 /pmc/articles/PMC8269399/ /pubmed/34244967 http://dx.doi.org/10.1007/s15010-021-01657-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Report
Koehler, Johanna
Ritzer, Barbara
Weidlich, Simon
Gebhardt, Friedemann
Kirchhoff, Chlodwig
Gempt, Jens
Querbach, Christiane
Hoffmann, Dieter
Haller, Bernhard
Schmid, Roland M.
Schneider, Jochen
Spinner, Christoph D.
Iakoubov, Roman
Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany
title Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany
title_full Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany
title_fullStr Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany
title_full_unstemmed Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany
title_short Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany
title_sort use of monoclonal antibody therapy for nosocomial sars-cov-2 infection in patients at high risk for severe covid-19: experience from a tertiary-care hospital in germany
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269399/
https://www.ncbi.nlm.nih.gov/pubmed/34244967
http://dx.doi.org/10.1007/s15010-021-01657-y
work_keys_str_mv AT koehlerjohanna useofmonoclonalantibodytherapyfornosocomialsarscov2infectioninpatientsathighriskforseverecovid19experiencefromatertiarycarehospitalingermany
AT ritzerbarbara useofmonoclonalantibodytherapyfornosocomialsarscov2infectioninpatientsathighriskforseverecovid19experiencefromatertiarycarehospitalingermany
AT weidlichsimon useofmonoclonalantibodytherapyfornosocomialsarscov2infectioninpatientsathighriskforseverecovid19experiencefromatertiarycarehospitalingermany
AT gebhardtfriedemann useofmonoclonalantibodytherapyfornosocomialsarscov2infectioninpatientsathighriskforseverecovid19experiencefromatertiarycarehospitalingermany
AT kirchhoffchlodwig useofmonoclonalantibodytherapyfornosocomialsarscov2infectioninpatientsathighriskforseverecovid19experiencefromatertiarycarehospitalingermany
AT gemptjens useofmonoclonalantibodytherapyfornosocomialsarscov2infectioninpatientsathighriskforseverecovid19experiencefromatertiarycarehospitalingermany
AT querbachchristiane useofmonoclonalantibodytherapyfornosocomialsarscov2infectioninpatientsathighriskforseverecovid19experiencefromatertiarycarehospitalingermany
AT hoffmanndieter useofmonoclonalantibodytherapyfornosocomialsarscov2infectioninpatientsathighriskforseverecovid19experiencefromatertiarycarehospitalingermany
AT hallerbernhard useofmonoclonalantibodytherapyfornosocomialsarscov2infectioninpatientsathighriskforseverecovid19experiencefromatertiarycarehospitalingermany
AT schmidrolandm useofmonoclonalantibodytherapyfornosocomialsarscov2infectioninpatientsathighriskforseverecovid19experiencefromatertiarycarehospitalingermany
AT schneiderjochen useofmonoclonalantibodytherapyfornosocomialsarscov2infectioninpatientsathighriskforseverecovid19experiencefromatertiarycarehospitalingermany
AT spinnerchristophd useofmonoclonalantibodytherapyfornosocomialsarscov2infectioninpatientsathighriskforseverecovid19experiencefromatertiarycarehospitalingermany
AT iakoubovroman useofmonoclonalantibodytherapyfornosocomialsarscov2infectioninpatientsathighriskforseverecovid19experiencefromatertiarycarehospitalingermany

Ejemplares similares